Synthetic affibody molecules:: A novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors

被引:165
作者
Orlova, Anna
Tolmachev, Vladimir
Pehrson, Rikard
Lindborg, Malin
Tran, Thuy
Sandstrom, Mattias
Nilsson, Fredrik Y.
Wennborg, Anders
Abrahmsen, Lars
Feldwisch, Joachim
机构
[1] Affibody AB, SE-16102 Bromma, Sweden
[2] Uppsala Univ, Rudbeck Lab, Dept Oncol Radiol & Clin Immunol, Uppsala, Sweden
[3] Univ Uppsala Hosp, Dept Hosp Phys, Uppsala, Sweden
关键词
D O I
10.1158/0008-5472.CAN-06-2887
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Affibody molecule Z(HER2:342-pep2), site-specifically and homogeneously conjugated with a 1,4,7,10-tetra-azacylododecane-N,N', N",N '''-tetraacetic acid (DOTA) chelator, was produced in a single chemical process by peptide synthesis. DOTA-Z(HER2:342-pep2) folds spontaneously and binds HER2 with 65 pmol/L affinity. Efficient radiolabeling with > 95% incorporation of In-111 was achieved within 30 min at low (room temperature) and high temperatures (up to 90 degrees C). Tumor uptake of In-111-DOTA-Z(HER12:342-pep2) was specific for HER2-positive xenografts. A high tumor uptake of 23% injected activity per gram tissue, a tumor-to-blood ratio of > 7.5, and high-contrast gamma camera images were obtained already I h after injection. Pretreatment with Herceptin did not interfere with tumor targeting, whereas degradation of HER2 using the heat shock protein 90 inhibitor 17-allylamino-geldanamycin before administration of In-111-DOTA-Z(HER2:342-pep2) obliterated the tumor image. The present results show that radiolabeled synthetic DOTA-Z(HER2:342-pep2) has the potential to become a clinically useful radiopharmaceutical for in vivo molecular imaging of HER2-expressing carcinomas.
引用
收藏
页码:2178 / 2186
页数:9
相关论文
共 51 条
[1]   Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab [J].
Adams, CW ;
Allison, DE ;
Flagella, K ;
Presta, L ;
Clarke, J ;
Dybdal, N ;
McKeever, K ;
Sliwkowski, MX .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (06) :717-727
[2]   A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice [J].
Adams, GP ;
Shaller, CC ;
Dadachova, E ;
Simmons, HH ;
Horak, EM ;
Tesfaye, A ;
Klein-Szanto, AJP ;
Marks, JD ;
Brechbiel, MW ;
Weiner, LM .
CANCER RESEARCH, 2004, 64 (17) :6200-6206
[3]   Fast and faster:: A designed variant of the B-domain of protein A folds in 3 μsec [J].
Arora, P ;
Oas, TG ;
Myers, JK .
PROTEIN SCIENCE, 2004, 13 (04) :847-853
[4]  
Aunoble B, 2000, INT J ONCOL, V16, P567
[5]  
BAUM R, 2006, J NUCL MED S1, V47, pP108
[6]  
Behr TM, 2001, Q J NUCL MED, V45, P189
[7]  
Behr TM, 1997, CANCER-AM CANCER SOC, V80, P2591, DOI 10.1002/(SICI)1097-0142(19971215)80:12+<2591::AID-CNCR35>3.0.CO
[8]  
2-5
[9]  
Britz-Cunningham SH, 2003, J NUCL MED, V44, P1945
[10]   HER2 expression in breast cancer primary tumours and corresponding metastases.: Original data and literature review [J].
Carlsson, J ;
Nordgren, H ;
Sjöström, J ;
Wester, K ;
Villman, K ;
Bengtsson, NO ;
Ostenstad, B ;
Lundqvist, H ;
Blomqvist, C .
BRITISH JOURNAL OF CANCER, 2004, 90 (12) :2344-2348